Found: 19
Select item for more details and to access through your institution.
Riluzole, a glutamate modulator, slows cerebral glucose metabolism decline in patients with Alzheimer's disease.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Development of a selective estrogen β‐receptor phytoestrogen formulation – PhytoSERM – for the reduction of Alzheimer's risk and relief of menopausal symptoms in women: a phase 2 randomized clinical trial framework.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, n. 21, p. 1, doi. 10.1002/alz.080295
- By:
- Publication type:
- Article
Allopregnanolone as a Regenerative Therapeutic for Alzheimer's Disease: Phase 2 proof‐of‐concept clinical trial using hippocampal volume as a surrogate endpoint.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.068251
- By:
- Publication type:
- Article
O4‐09‐06: MRI, FDG, AND EARLY FRAME AMYLOID IMAGE CLASSIFIERS TO CHARACTERIZE AND DIFFERENTIATE ALZHEIMER'S DISEASE VARIANTS AND NON‐AD DEMENTIAS.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P1429, doi. 10.1016/j.jalz.2018.06.2962
- By:
- Publication type:
- Article
P3‐031: THE CRITICAL PATH FOR ALZHEIMER'S DISEASE: HIPPOCAMPAL VOLUME AS AN ENRICHMENT BIOMARKER IN TRIALS OF PATIENTS WITH MILD COGNITIVE IMPAIRMENT.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P1076, doi. 10.1016/j.jalz.2018.06.1386
- By:
- Publication type:
- Article
P1‐380: MRI CLASSIFIERS CHARACTERIZE MILD TRAUMATIC BRAIN INJURY IN SYMPTOMATIC AND PRESYMPTOMATIC STAGES AND DIFFERENTIATE FROM ALZHEIMER'S DISEASE–RELATED IMPAIRMENT.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P443, doi. 10.1016/j.jalz.2018.06.388
- By:
- Publication type:
- Article
TAU PATHOLOGY ACCUMULATION IS PREDICTED BY A PROGRESSIVE PATTERN OF GLUCOSE HYPOMETABOLISM INITIATING IN PRECLINICAL STAGES.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P1101, doi. 10.1016/j.jalz.2017.06.1590
- By:
- Publication type:
- Article
THE COALITION AGAINST MAJOR DISEASES: TOWARD U.S. FDA QUALIFICATION OF HIPPOCAMPAL VOLUME AS A BIOMARKER FOR ENRICHMENT IN CLINICAL TRIALS FOR PRE-DEMENTIA STAGES OF ALZHEIMER'S DISEASE.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P1259, doi. 10.1016/j.jalz.2017.06.1878
- By:
- Publication type:
- Article
RELATIONSHIPS BETWEEN TAU BURDEN MEASURED USING AV1451 PET, REGIONAL CEREBRAL GLUCOSE METABOLISM, AND COGNITIVE STATUS.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016, v. 12, p. P1169, doi. 10.1016/j.jalz.2016.07.090
- By:
- Publication type:
- Article
COMBINING NEURODEGENERATIVE CHARACTERIZATION WITH AMYLOID BURDEN MEASUREMENT USING AN EARLY FRAME AMYLOID PET MULTIVARIATE CLASSIFIER.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016, v. 12, p. P1082, doi. 10.1016/j.jalz.2016.06.2262
- By:
- Publication type:
- Article
MEASUREMENT OF AMYLOID BURDEN USING THE EARLY FRAMES OF AMYLOID PET AND A MULTIVARIATE CLASSIFIER.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016, v. 12, p. P924, doi. 10.1016/j.jalz.2016.06.1913
- By:
- Publication type:
- Article
Neurodegenerative variability among amyloid positive MCI patients: Implications for clinical trials and clinical care.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2015, v. 11, n. 7, p. P143, doi. 10.1016/j.jalz.2015.07.066
- By:
- Publication type:
- Article
Regional cerebral glucose metabolism provides a sensitive and specific marker of Alzheimer's disease, frontotemporal dementia and mild cognitive impairment, and correlates with cerebrospinal fluid Abeta42 level decline in cognitively normal subjects
- Published in:
- 2010
- By:
- Publication type:
- Abstract
Hippocampal glucose metabolism predicts cognitive decline and correlates to disease progression in the ADNI population
- Published in:
- 2009
- By:
- Publication type:
- Abstract
Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients.
- Published in:
- Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2024, v. 10, n. 3, p. 1, doi. 10.1002/trc2.12490
- By:
- Publication type:
- Article
Development, initial validation, and application of a visual read method for [<sup>18</sup>F]MK‐6240 tau PET.
- Published in:
- Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2023, v. 9, n. 1, p. 1, doi. 10.1002/trc2.12372
- By:
- Publication type:
- Article
Measurement of neurodegeneration using a multivariate early frame amyloid PET classifier.
- Published in:
- Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2022, v. 8, n. 1, p. 1, doi. 10.1002/trc2.12325
- By:
- Publication type:
- Article
Exploratory imaging outcomes of a phase 1b/2a clinical trial of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: Structural effects and functional connectivity outcomes.
- Published in:
- Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2022, v. 8, n. 1, p. 1, doi. 10.1002/trc2.12258
- By:
- Publication type:
- Article
Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer’s dementia.
- Published in:
- Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2021, v. 7, n. 1, p. 1, doi. 10.1002/trc2.12106
- By:
- Publication type:
- Article